Cerevel Therapeutics has begun a study of an experimental drug called CVL-751 as a possible treatment for people with Parkinson’s disease. 

Currently recruiting

About this study

The main purpose of this study is to learn how safe the study is and how well it works. This is a randomised, double-blinded trial for people in the early stages of Parkinson's disease.

Contact us to find out more about this research study, quoting reference number 2020.027

Who can take part

Participants must meet the following criteria:

  • People aged 40 to 80 years, inclusive
  • People who are sexually active must agree to use acceptable (at minimum) or highly effective birth control
  • Individuals must be capable of giving signed informed consent
  • Individuals who are able, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures

What's involved

  • Visits every three weeks for the duration of the study
  • Blood tests
  • ECG
  • Complete questionnaires
Person handling test tubes for research


All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.

This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.

The RMH Clinical Trials Centre
Clinical Trials Centre

The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.

The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.

Related services